Background illustration for clinical trials search

Paid Clinical Trials Fullerton

Discover 3,591 paid clinical trials in Fullerton, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Featured

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

for
Early Breast Cancer
Location: Fountain Valley CA, Sterling Heights MI, Pittsburgh PA,
Sponsor: Genentech, Inc.

Sex: Female

Age: 18+

Code: NCT07541079

Phase 3, Recruiting
Featured

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

for
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Location: Tustin CA, Red Oak TX, Jackson TN, Orland Park IL,
Sponsor: AbbVie

Sex: All

Age: 18 - 70+

Code: NCT07607964

Phase 1, Recruiting
Featured

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

for
Obesity or Overweight, Type 2 Diabetes Mellitus
Location: Long Beach CA, Montclair CA, Lake Forest CA, Norco CA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07351058

Phase 3, Recruiting
Featured

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non Small Cell Lung Cancer, c-MET
Location: Huntington Beach CA, Duarte CA, Irvine CA, Lancaster CA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT04928846

Phase 3, Recruiting
Featured

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

for
Alzheimer's Disease
Location: Irvine CA, Boulder CO, Dallas TX, Cordova TN,
Sponsor: AbbVie

Sex: All

Age: 50 - 70+

Code: NCT07599670

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Irvine CA, Orange CA, Newport Beach CA, Los Angeles CA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06793215

Phase 3, Recruiting
Featured

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

for
Atherosclerosis
Location: Irvine CA, Beverly Hills CA, Los Angeles CA,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT07448038

Phase 2, Recruiting
Featured

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

for
Obesity or Overweight
Location: Irvine CA, San Diego CA, Walnut Creek CA, Tucson AZ,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07351045

Phase 3, Recruiting
Featured

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for
Non-Squamous Non-Small Cell Lung Cancer, c-MET
Location: Newport Beach CA, Duarte CA, Irvine CA, Los Angeles CA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07005102

Phase 2, Phase 3, Recruiting
Featured

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for
Moderately to Severely Active Crohns Disease
Location: Newport Beach CA, Santa Clarita CA, Lancaster CA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819891

Phase 3, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

for
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer,
Location: Duarte CA, Irvine CA, Santa Monica CA, Stanford CA,
Sponsor: Hoffmann-La Roche

Sex: Female

Age: 18+

Code: NCT04802759

Phase 1, Phase 2, Recruiting
Featured

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

for
Lymphoma
Location: Duarte CA, Los Angeles CA, Santa Monica CA, Reno NV,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06084936

Phase 3, Recruiting
Featured

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for
Metastatic Breast Cancer
Location: Duarte CA, Irvine CA, Corona CA, Burbank CA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05894239

Phase 3, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, c-MET
Location: Duarte CA, Irvine CA, La Jolla CA, Vancouver WA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07155187

Phase 2, Phase 3, Recruiting
Featured

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

for
Small Cell Lung Cancer
Location: Duarte CA, Irvine CA, Goodyear AZ, Eugene OR,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07365241

Phase 3, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

for
Acute Myeloid Leukemia
Location: Duarte CA, Houston TX, St Louis MO, Atlanta GA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07581002

Phase 2, Phase 3, Recruiting
Featured

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

for
Multiple Myeloma
Location: Duarte CA, Irvine CA, Cincinnati OH, Atlanta GA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07555938

Phase 3, Recruiting
Featured

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

for
Multiple Myeloma
Location: Duarte CA, Irvine CA, Denver CO, Chicago IL,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07409246

Phase 1, Recruiting
Featured

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

for
Advanced Squamous Tumors
Location: Duarte CA, Irvine CA, Irving TX, Chicago IL,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07241039

Phase 1, Recruiting
Featured

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

for
Colorectal Cancer
Location: Duarte CA, Goodyear AZ, Aurora CO, Portland OR,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07525206

Phase 3, Recruiting